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Recent identifications of associations between novel variants in inflammation-related genes and several common diseases
emphasize the need for systematic evaluations of these genes in disease susceptibility. Considering that many genes are
involved in the complex inflammation responses and many genetic variants in these genes have the potential to alter the
functions and expression of these genes, we assembled a list of key inflammation-related genes to facilitate the identification
of genetic associations of diseases with an inflammation-related etiology. We first reviewed various phases of inflammation
responses, including the development of immune cells, sensing of danger, influx of cells to sites of insult, activation and
functional responses of immune and non-immune cells, and resolution of the immune response. Assisted by the Ingenuity
Pathway Analysis, we then identified 17 functional sub-pathways that are involved in one or multiple phases. This organization
would greatly increase the chance of detecting gene-gene interactions by hierarchical clustering of genes with their functional
closeness in a pathway. Finally, as an example application, we have developed tagging single nucleotide polymorphism (tSNP)
arrays for populations of European and African descent to capture all the common variants of these key inflammation-related
genes. Assays of these tSNPs have been designed and assembled into two Affymetrix ParAllele customized chips, one each for
European (12,011 SNPs) and African (21,542 SNPs) populations. These tSNPs have greater coverage for these inflammation-
related genes compared to the existing genome-wide arrays, particularly in the African population. These tSNP arrays can
facilitate systematic evaluation of inflammation pathways in disease susceptibility. For additional applications, other
genotyping platforms could also be employed. For existing genome-wide association data, this list of key inflammation-related
genes and associated subpathways can facilitate comprehensive inflammation pathway- focused association analyses.
Citation: Loza MJ, McCall CE, Li L, Isaacs WB, Xu J, et al (2007) Assembly of Inflammation-Related Genes for Pathway-Focused Genetic Analysis. PLoS
ONE 2(10): e1035. doi:10.1371/journal.pone.0001035
INTRODUCTION
Inflammation is an essential component of immune-mediated
protection against pathogens and tissue damage. Immune
responses are also responsible for the unfavorable rejection of
tissue/organ transplants, hypersensitivity reactions (e.g., atopy,
anaphylaxis, contact hypersensitivity, delayed-type hypersensitiv-
ity), and septic shock. Aberrant or unchecked immune responses
may lead to a state of chronic inflammation [1–3]. This may occur
when the immune response: 1) is activated in the absence of
‘danger’ signals; 2) fails to fully turn-off (resolve) after elimination
of the danger; and 3) fails to completely clear the danger stimulus.
Factors that may influence the initiation, activity, and resolution of
immune responses include health (physical and emotional), age,
diet, medications, and genetic predisposition.
Inflammation may also be a contributing factor for some
diseases. The role of chronic inflammation in a wide variety of
diseases is well-appreciated, including rheumatoid arthritis and
other autoimmune disorders [4], cardiovascular disease [5–7],
gastrointestinal disorders [8,9], and a number of cancers [10–14].
Perhaps the best evidence for the importance of chronic
inflammation in disease is the efficacy of NSAIDs in reducing
the risk or severity of these disorders [15]. There is mounting
evidence that dietary factors that may influence inflammation,
such as the balance of omega-3 vs. omega-6 polyunsaturated fatty
acids (PUFAs), have an impact on disease risk and progression
[16]. Genetic studies also provide evidence that variant alleles of
genes associated with inflammatory pathways impact the risk of
disease initiation, progression, and severity (see Table 1). The role
of inflammation as a mediator of disease is currently receiving
extensive attention, resulting in the National Institute of Allergy
and Immunologic Diseases (NIAID) plans for an NIH Roadmap
initiative with the overarching theme: ‘‘Inflammation as a Com-
mon Mechanism of Disease’’ (http://nihroadmap.nih.gov/in-
flammation/index.asp).
Numerous genetic linkage and case-control association studies
have implicated genetic variations in genes important in immunity
and inflammation and inflammatory diseases. Single missense
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PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1035heritable mutations can be the sole or major determinant for
inflammatory diseases, such as Familial Cold Autoinflammatory
Syndrome (missense mutations in exon 3 of Cias1 account for
all cases) [17–19] and Familial Mediterranean Fever (MEFV,
five founder missense mutations, when homozygous, account for
74% of cases) [20]. For many complex inflammatory diseases,
polymorphisms in inflammatory genes are more likely to act as
modifiers for disease susceptibility rather than sole determinants.
Recent meta-analyses report modest associations between single
nucleotide polymorphisms (SNPs) in TNF (encoding TNF-a) and
increased risk for asthma [21], system lupus erythamatosus (SLE)
[22], and psoriatic arthritis [23]. A variant of PTPN22 (encoding
a lymphoid-specific protein tyrosine phosphatase) is modestly
associated with multiple autoimmune diseases (rheumatoid
arthritis, SLE, type 1 diabetes, and Graves’ disease) [24].
Associations of IRF5 (interferon regulator factor 5) genetic variants
and increased SLE risk have been highly replicated [25]. IFIH1,
encoding an innate immunity viral mRNA detector (early type I
IFN-b responsive gene, Helicard), is strongly associated with type
1 diabetes risk [26]. Association of a small risk for type 1 diabetes
and CTLA4 has been consistently replicated [27–29]. An insertion
polymorphism in CARD15, the gene encoding the microbial
nucleotide detector Nod2, is a major risk factor for Crohn’s disease
[30]. An association between SNP’s in IL23R (IL-23 receptor b-
chain) and increased risk of inflammatory bowel disease has been
reported for a genome-wide association study and confirmed in
three independent populations [31]. A recent meta-analysis
demonstrated that an IL4R (IL-4 receptor alpha chain) variant
modestly increases risk for atopic asthma [32]. A description of
these studies and reported associations is provided in Table 1.
This list is not intended to be comprehensive but rather serves as
an example of representative genetic variations which have been
well-established to be associated with common inflammatory
disorders.
In addition to inflammatory/autoimmune diseases, polymorph-
isms in inflammation-associated genes may also contribute to risk
for diseases in which inflammatory/immune-disorders are not the
primary characteristic. There is evidence from the Breast Cancer
Table 1. Confirmed associations of genetic variants in inflammation-associated genes and disease.
..................................................................................................................................................
Disease Gene Encoded protein Variant Odds ratio
a p-value Confirmation method
Age-related macular
degeneration [44]
CFH Complement factor H rs1061170 3.40
b ,1610
25 Case-control/meta-analysis
Atopic asthma [32] IL4R IL-4 receptor alpha rs1801275 1.79 3610
29 Meta-analysis of 7 study populations
Atopic asthma [21] TNF TNF-alpha -308 G/A 1.46 1610
24 Meta-analysis of 15 study populations
Crohn’s disease [30] CARD15 Nod2 1007fsinsC 4.3 7610
228 Meta-analysis of 16 study populations
Breast cancer [33] CASP8 Caspase-8 rs1045485 0.90 0.016 Analysis of 3 study populations (6351
cases/5708 controls)
Breast cancer [33] TGFB1 TGF-beta 1 rs1982073 1.08 0.0088 Analysis of 3 study populations (6863
cases/5587 controls)
Breast cancer [34] TNF TNF-alpha rs361525 1.18 0.008 Analysis of two independent study
populations
Graves’ disease [24] PTPN22 Lymphoid-specific
phosphatase
C1858T 1.61 ,1610
25 Meta-analysis of 3 study populations
Inflammatory bowel
disease [31]
IL23R IL-23 receptor beta rs11209026 0.26 5610
29 Genome-wide screen (raw p-value)
0.45 8610
24 Case-control replication
,0.5
c 1.3610
210 Family-based TDT replication
Psoriatic arthritis [23] TNF TNF-alpha -238 G/A 2.29 2610
24 Meta-analysis of 8 study populations
Rheumatoid arthritis [24] PTPN22 Lymphoid-specific
phosphatase
C1858T (R620W) 1.68 ,1610
25 Meta-analysis of 12 study populations
Systemic lupus
erythamatosus [25]
IRF5 Interferon response
factor 5
rs2004640 1.47 4.2610
221 Case-control/meta-analysis+replication in
family-based
Systemic lupus
erythamatosus [24]
PTPN22 Lymphoid-specific
phosphatase
C1858T (R620W) 1.49 ,1610
25 Meta-analysis of 5 study populations
Systemic lupus
erythamatosus [22]
TNF TNF-alpha -308 G/A 2.1 ,0.001 Meta-analysis of 10 study populations of
European descent
Type 1 diabetes [29] CTLA4 CTLA-4 rs3087243 1.18
c 5.6610
26 Family-based TDT
Type 1 diabetes [28] CTLA4 CTLA-4 rs3087243 1.17
c 6610
24 Family-based TDT
1.21 1.3610
27 Case-control
Type 1 diabetes [27] CTLA4 CTLA-4 rs3087243 1.20 3.7610
210 Case-control
Type 1 diabetes [26] IFIH1 Mda-5, Helicard rs1990760 0.86 1.42610
210 Genome-wide, validated in case-
control+family-based
Type 1 diabetes [24] PTPN22 Lymphoid-specific
phosphatase
C1858T (R620W) 1.85 ,1610
25 Meta-analysis of 6 study populations
aOdds ratio for allele test (multiplicative model), unless otherwise indicated.
bOdds ratio for dominant model
cRisk ratio from family-based transmission disequilibrium test (TDT).
doi:10.1371/journal.pone.0001035.t001
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Inflammation Pathway Analysis
PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e1035Association Consortium that CASP8 (caspase 8) and TGFB1 (TGF-
b1) variants impart risk, albeit low penetrance, for breast cancer
[33]. Analysis of two independent populations suggest that a rare
polymorphism in TNF may also be a low-penetrance risk factor for
breast cancer [34]. Several groups report associations between
various PTGS2 (COX-2) genetic variants and colorectal cancer risk
[35–39].ThereisalsoevidencetosuggestthatalowfrequencyCOX2
variant allele decreases prostate cancer risk [40], particularly in
subjects who frequently eat fish [41]. Interestingly, in a preliminary
study using MegAllele
TM I&I panel, including 9,275 SNPs in 1,086
genes involved in immunity and inflammation, more SNPs were
found to be significantly associated with prostate cancer risk than
expected by chance, which suggests multiple genetic variants in this
pathway impart modest risk to prostate cancer [42].
Because genetic associations of disease and genetic variations in
inflammatory genes are often relatively modest, it is likely that
polymorphisms in multiple inflammatory genes cooperate in an
additive or synergistic manner to impact disease risk. Pathway
analyses may help to reveal gene-gene interactions or risks imparted
independently from other genes in the pathway. The advantages of
performing analyses at pathway levels are illustrated by Dinu et al.
[43]. Associations between CFH (complement factor H) and age-
related macular degeneration have been replicated in numerous
studies [44]. To test whether genetic variations in the multiple
complement pathway genes impact macular degeneration risk, Dinu
et al. analyzed the existing genome-wide association study data of
Klein et al. [45], restricting the analyses to genes in the complement
pathway in subjects carrying the CFH risk allele. Significant
associations were detected for a C7 and MBL2 variants and severity
of macular degeneration in the context of the complement pathway
analysis and the CHF risk allele, and these associations would not
have been significant in a genome-wide analysis of the data.
RESULTS
Choosing genes
Various aspects of immunity contribute to the development of an
overall inflammatory immune response. These phases include the
development of immune cells, sensing of danger, influx of cells to
sites of insult, activation and functional responses of immune and
non-immune cells, and resolution of the immune response. To
broadly cover most aspects of inflammatory responses, the various
phases of immune responses were considered in choosing genes for the
SNP array panel, outlined in Table 2. A schematic representation
of most of these phases is presented in Fig. 1.
Priority was given first to genes of known function in
inflammatory responses (in both immune and non-immune cells),
and then to genes expressed in immune cells with function implied
by homology to other genes but exact function not clear.
Ubiquitously expressed genes required for the normal function
of most cell types of diverse origin were given lower priority.
However, special emphasis was placed on genes at nodes for
signaling to and from multiple pathways, most notably genes in
NF-kB, MAPK, and PI3K signaling pathways.
Pathways were built using Ingenuity Pathways Analysis, as
described in Methods section, using both pre-defined ‘canonical
pathways’ and custom-built pathways based on our own queries
for genes/pathways not included in the canonical pathways.
Multiple functional pathways are involved each of the immune
response phases, and each functional pathway may contribute to
several of the immune response phases. For example (Fig. 2), the
response of a macrophage responding to a danger signal during
a gram-negative bacterial infection involves innate pathogen
recognition of LPS by the TLR4 complex. TLR4 transduces
signals via NF-kB, MAPK, and PI3K signaling pathways,
stimulating synthesis of eicosanoids and cytokines to signal other
cells of the danger. LPS may also stimulate expression of stress-
induced proteins, such as MIC-A and MIC-B (ligands for natural
killer cell activating receptors) and T cell co-stimulatory molecules
(B7 family proteins).
Because immune response phases utilize multiple functional
pathways and these pathways are overlapping among phases, the
genes chosen for the SNP array panel were assigned to one of the
following functional pathways:
Adhesion-Extravasation-Migration: adhesion molecules;
chemoattractants and chemoattractant receptors; cytoskeletal
rearrangement signaling, motility proteins.
Apoptosis signaling: death receptors and ligands and
extrinsic apoptosis pathway signaling; mitochondrial-dependent,
intrinsic apoptosis pathway signaling; cellular stress signaling.
Table 2. Phases of immune response.
..................................................................................................................................................
Phase of immune response Description
Hematopoiesis/homeosta-sis/tolerance The generation and differentiation of immune cells and maintenance of their number in circulation and tissues;
prevention of self-reactivity.
Danger signal Innate recognition of and response to pathogenic foreign substances or stress.
Mobilization of immune cells Systemic soluble mediators informing immune cells in circulation and lymphoid tissues of danger.
Extravasation The process of circulating immune cells crossing from blood into peripheral tissues and secondary lymphoid tissues.
Migration to site of inflammation The process of immune cells, after extravasation, reaching the site of inflammatory insult, including
chemoattraction, adhesion to substrates, and degradation of extracellular matrix.
Interactions between resident cells, immune
cells, and pathogens at site of inflammation
Interactions between resident cells, immune cells, and pathogens at site of inflammation–how infiltrating cells
interact with the resident inflammatory cells, non-immune cells (e.g., epithelia), pathogens, and other infiltrating
cells, that leads to activation of effector functions.
Activation of inflammatory cells The signaling pathways and transcription factors stimulated by activating, co-stimulatory, and inhibitory receptors
that leads to activation, proliferation, differentiation, and survival of responding immune cells.
Effector functions of inflammatory cells The factors produced/released by immune cells in attempt to resolve the pathogenic insults, including release of
cytotoxic/cytostatic mediators and mediators to enhance or fine-tune the immune response.
Response of target cells The pathways in non-immune cells (e.g., epithelia) activated in response to the effector functions of immune cells.
Resolution of immune response vs. chronic
inflammation
The pathways that lead to the downregulation of immune responses and inflammation after the pathogenic insult
is cleared; the factors maintaining late-phase immune responses when the insult is not totally resolved.
doi:10.1371/journal.pone.0001035.t002
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Inflammation Pathway Analysis
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1035Calcium signaling: NF-ATs; calcineurins; calcium/calmod-
ulin-dependent kinases.
Complement cascade: components of classical, alternative,
and lectin-dependent complement pathways.
Cytokines and cytokine signaling: cytokines; cytokine
receptors; cytokine-dependent signaling, including JAK-STAT
and interferon-regulatory factor (IRF) pathways; suppressor of
cytokine signaling proteins (SOCS).
Eicosanoid synthesis and receptors: enzymes involved in
synthesis of prostanoids, leukotrienes, hepoxylins (12-HETE), and
lipoxins from arachidonic acid; prostanoid and leukotriene
receptors.
Glucocorticoid/PPAR signaling: nuclear receptors for
glucocorticoids; steroid-interacting proteins; PPARs and associated
proteins.
G-Protein Coupled Receptor Signaling: GPCRs (other
than eicosanoid receptors and chemokine receptors); G-protein-
dependent signaling pathways, including cAMP-PKA and phos-
pholipase B2.
Innate pathogen detection: Toll-like receptors (TLRs);
intracellular nucleotide detectors (e.g., Nod1 and putative
members of CARD/Nod family); peptidoglycan recognition
proteins; associated signaling molecules linking these detectors to
major signaling pathways.
Leukocyte signaling: Signaling molecules, receptors, and
adaptors important for regulation of leukocyte activation beyond
major signaling pathways (i.e., MAPK, PI3K/Akt, NF-kB, GPCR,
and cytokine signaling pathways); including, but not limited to, T
cell receptor (TCR) and B cell receptor (BCR) signaling
components, B7 family, phosphatases, Foxp3, immunoglobulin
receptors, leukocyte inhibitory receptor (CD85) family, scavenger
receptors.
MAPK signaling: p38 stress-activated protein kinase, p42/
p44 extracellular-regulated kinase (Erk), and Jun kinase (Jnk)
signaling pathways.
Natural Killer Cell Signaling: Natural killer (NK) cell-
specific activating and inhibitory receptors; adaptors and signaling
molecules for transducing NK cell-specific receptor signaling.
NF-kB signaling: Molecules for regulation of NF-kB
activation, including adaptors linking. other pathways to and
from the NF-kB pathway (e.g., from MAPK, pathogen-detection,
and TNF-a signaling pathways).
Antigen presentation: Major Histocompatibility Complex
(MHC) molecules and associated proteins; proteins involved in
uptake, processing, and loading of peptides on MHC molecules.
PI3K/AKT Signaling: Molecules involved in regulation of
PI3K-dependent signaling, including adaptors linking other path-
ways to and from the PI3K pathway.
Figure 1. Development of an immune response. Depicted is a schematic representation of an immune response to a generic pathogenic insult. The
phases of immune responses (described in Table 2) are shown in bold. Additional aspects not shown are the involvement of secondary lymphoid
tissues for initial T cell and B cell activation by dendritic cells that migrate from the site of inflammation to lymph nodes and other secondary
lymphoid structures. The resolution of immune responses, immunological memory, and homeostasis are also not depicted.
doi:10.1371/journal.pone.0001035.g001
Inflammation Pathway Analysis
PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1035ROS/glutathione/cytotoxic granules: Molecules involved
in the generation and response to leukocyte-derived cytotoxic agents
(reactive oxygen species (ROS), nitric oxide, cytotoxic granules of
granulocytes and natural killer cells), including contents of
granulocyteand NKcellcytotoxicgranules; glutathioneperoxidases;
peroxiredoxins; catalase; proteinases; superoxide dismutase.
TNF superfamily and signaling: Receptors and ligands of
the TNF-a superfamily; adaptors and signaling molecules involved
in transducing signals from receptor stimulation to other major
signaling pathways (e.g., MAPK and NF-kB pathways).
Examples of the functional subpathways and types of genes
chosen for the different phases of immune responses are presented
in Table 3 (proteins encoded by the genes are provided). Most of
these immune response phases also utilize common signaling
pathways, including elements of MAPK, NF-kB, PI3K/Akt,
GCPR, cytokine, and leukocyte signaling pathways. An example
of the integration of multiple functional subpathways for one phase
of an immune response (danger signal) is depicted in Fig. 2. The
numbers of genes chosen in each subpathway are listed in Table 4,
and the complete list of 1027 candidate genes and their primary
subpathway (and secondary subpathway for a subset of genes) is
provided in Supplementary Table S1.
Example application: WFINFLAM tSNP panel
Because the components comprising inflammation are very
numerous and interacting across many pathways, without strong
a priori evidence it is difficult to choose a handful of candidate
genes to fully cover the potential genetic risk factors contributing
to the inflammatory component of a particular disease. For this
reason, panels of single nucleotide polymorphisms (SNPs) in an
array of inflammation-related genes broadly covering most aspects
of immunity and inflammation based on our assembled list will
be critical in objectively evaluating the impact of genetic variations
in inflammation-related genes on an inflammation-dependent
outcome.
There is a commercially available product, Affymetrix Gene-
ChipH Human Immune and Inflammation 9K SNP panel, that
attempts to serve the purpose. This application -specific panel
contains ,9,000 SNPs to cover ,1,000 immunity- and in-
flammation- related genes (http://www.affymetrix.com/support/
technical/datasheets/humanimmune_9k_snp_datasheet.pdf).
However, the rationale for choosing the ,1,000 immunity and
inflammation genes in this panel is not clear, and the coverage of
these genes, regardless of their biological functions, may not be
sufficient. In order to investigate the impact of genetic variations in
Figure 2. Inflammation subpathways involved in the response to danger signal. The concerted action of multiple functional subpathways in the
initial response of a macrophage to bacteria or virus is depicted. Solid arrows indicate signaling events and dashed arrows stimulated production of
proteins and other inflammatory mediators (including autocrine/paracrine responses of the macrophage to the released molecules).
doi:10.1371/journal.pone.0001035.g002
Inflammation Pathway Analysis
PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e1035a broad array of inflammation-related genes on disease risk, we
created two tagging SNP (tSNP) panels, one each for populations
with either Caucasian or African ancestries, for Affimetrix
ParAllele genotyping chips. These tSNP panels were designed to
capture majority of the genetic variations in these 1027
inflammation candidate genes.
tSNPs for the 1027 inflammation-associated candidate genes
were chosen based on a pair-wise r
2 threshold of 0.8 and MAF
$5% using data in the HapMap Phase II database (HapMap Data
Release 21a/phaseII; http://hapmap.org/index.html.en). tSNPs
were chosen separately for the CEU (representing European
ancestry) and YRI populations (representing African ancestry). In
order to accommodate as many relevant inflammation genes as
possible, less stringent criteria with r
2 threshold .0.5 were
employed for intronic regions (excluding 5kb in the beginning
and end of these big introns) greater than 50kb in certain large
genes with .100 tSNPs. There were seven genes in this category,
and the intronic regions for which a less stringent r
2 threshold was
applied are listed in Supplementary Table S2. For genes
without genotype information from HapMap, additional SNPs in
six inflammation genes were chosen to be included based on
information from other resources (see Supplementary Table
S3), as described in Methods section.
The resulting inflammation tSNP panels, WFINFLAM-CEU
for Caucasians and WFINFLAM-YRI for African descent, include
12,011 SNPs and 21,542 SNPs respectively in 1027 inflammation-
associated candidate genes. There is an average of 11.7 and 21
SNPs in each candidate gene in WFINFLAM-CEU and WFIN-
FLAM-YRI panels, respectively. Table 4 briefly summarizes the
numbers of genes and tSNPs included in each subpathway. The
annotation table for this panel, including the list of 1027 genes,
their chromosomal positions, their associated primary and
secondary subpathways, and the number of tSNPs chosen for
each gene can be found in Supplementary Table S1 (and also
our website: http://www1.wfubmc.edu/Genomics/Publications+
and+Data/). Additionally, the annotation file for the SNPs
included in the WFINFLAM-CEU and WFINFLAM-YRI panels,
including the chromosomal locations, their associated genes and
the sub-pathways, can also be found in Supplementary Tables
Table 3. Pathways and proteins associated with immune response phases.
..................................................................................................................................................
Phase of immune response Examples of pathways, proteins, and inflammatory mediators involved in immune response phases
Hematopoiesis/homeostasis/ tolerance hematopoietic cytokines (M-,G-,GM-CSF;IL-4,-5,-7,-13), stromal factors (c-kit, SCF, Flt3L), regulatory T cell function
(Foxp3)
Danger signal innate pathogen recognition receptors (TLRs, CARDs/NODs, peptidoglycan recognition proteins), scavenger
receptors (MSR1), endothelins, adenosine receptors, complement, stress-induced responses (MIC-A,-B), eicosanoid
synthesis genes, cytokines, antigen presentation genes
Mobilization of immune cells systemic inflammatory mediators (IL-1b, IL-6, TNF-a), chemokines, eicosanoids, GPCR signaling (eicosanoids,
histamines)
Extravasation adhesion molecules (integrins, -CAMs), chemokines, vasodilators (eicosanoids/GPCR), cytoskeletal rearrangement
singaling molecules (Vav, VASP, MENA), non-muscle myosins
Migration to site of inflammation adhesion molecules (integrins, -CAMs, maxtrix receptors), chemokines, matrix proteases (MMPs), cytoskeletal
rearrangement singaling molecules (Vav,VASP,MENA), focal adhesion proteins (Vav,ROCK), non-muscle myosins
Interactions between resident cells, immune cells,
and pathogens at site of inflammation
adhesion molecules, innate detectors of pathogens (TLRs, CARDs/NODs), Fc receptors (FcgRI,II,III; FceRI,II), stress-
induced ligands (MIC-A,-B), NK cell-activating receptors, cytokines and receptors, other activating receptors (TCR,
BCR complexes; growth factor receptors); co-stimulatory receptors (B7 family, CD2 family), inhibitory receptors (KIRs,
LIRs/ILTs), phagocytosis/antigen presentation (XBOX genes, CIITA, TAP, immunoproteasome, HLA molecules)
Activation of inflammatory cells MAPK pathways (Erk, p38, Jnk), PI3K/Akt signaling, NF-kB signaling, cytokine signaling (JAK/STAT/Tyk, NFIL3, NFIL6,
IRFs), GPCR signaling (PKA, PLCb, phosphodiesterases, CREB, Pyk2, Rap1, Src), adaptor signaling proteins (TRAFs,
IRAKs, MyD88, DAP10, DAP12, ZAP70, Syk, LAT, SLP76, MyD88, CD3f,F c eRc)
Effector functions of inflammatory cells cytokines (IFN-c, IFN-a,T N F - a superfamily, CSFs, interleukins), death receptor ligands (FasL, TRAIL, TNF-a),
eicosanoids (prostaglandins, thromboxane, prostacyclin, leukotrienes), cytotoxic mediators (glutathiones/PHOX/
reactive oxygen species, RNS, perforin/granzymes), antibody production, acute phase/fever response (C-reactive
protein, factor P)
Response of target cells cytokine receptors, GPCRs, death receptors, apoptosis signaling, adhesion molecules, growth factor receptors
Resolution of immune response vs. chronic
inflammation
apoptosis (death receptor and mitochondrial pathways), TGF-b, IL-10, Foxp3, prostaglandins, phosphatases,
inhibitors of cytokine signaling (SOCS, A20/TNFAIP3)
doi:10.1371/journal.pone.0001035.t003
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Table 4. Primary subpathways in inflammation panel.
......................................................................
Subpathway
Number of genes
in subpathway
Number of SNPs
in subpathway
Adhesion-Extravasation-Migration 142 1385
Apoptosis Signaling 68 682
Calcium Signaling 14 409
Complement Cascase 40 419
Cytokine signaling 172 1598
Eicosanoid Signaling 39 374
Glucocorticoid/PPAR signaling 21 230
G-Protein Coupled Receptor Signaling 42 1125
Innate pathogen detection 50 457
Leukocyte signaling 121 1743
MAPK signaling 118 1949
Natural Killer Cell Signaling 31 259
NF-kB signaling 33 297
Phagocytosis-Ag presentation 39 286
PI3K/AKT Signaling 37 307
ROS/Glutathione/Cytotoxic granules 22 162
TNF Superfamily Signaling 38 328
doi:10.1371/journal.pone.0001035.t004
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mics/Publications+and+Data/). The coverage for the 1027 in-
flammation candidate genes in CEU is better compared to other
widely used genome-wide association panels. For the coverage of
the 1027 inflammation-associated candidate genes, 90.4% of the
genes have 90% or more SNPs within these genes that can be
captured by r
2$0.8 in CEU using WFINFLAM-CEU panel,
compared to 78.9% for the Illumina HumanHap 550 genome-
wide panel and 45.8% for the Affymetrix 500k genome-wide
panel. For populations with African ancestry, the coverage for the
1027 inflammation candidate genes in YRI is greatly improved
compared to other widely used genome-wide association panels.
For the coverage of the 1027 inflammation-associated candidate
genes, 88.2% of the genes have 90% or more SNPs within these
genes that can be captured by r
2$0.8 in YRI using WFINFLAM-
YRI panel, compared to 27.1% for the Illumina HumanHap 650k
genome-wide panel (which was designed to capture more genetic
information from YRI population), and 12.5% for the Affymetrix
500k genome-wide panel. The coverage for all these genotyping
panels is detailed in Supplementary Table S6.
DISCUSSION
Various components and complex interactions comprise immune
and inflammation responses, and numerous genes are involved in
this complex network. With a thorough review of various aspects
of inflammatory immune responses, and a systematic search for
gene-gene interactions using Ingenuity Pathway Analysis, we have
provided a comprehensive list of inflammation-associated genes
and subpathways for genetic association studies.
Genome-wide association studies have been a very popular
approach to test the association between disease phenotypes and
genetic variations. However, we believe there are still several
advantages for a pathway-focused study. First of all, compared to
whole-genome analyses, restricting analyses to SNPs in a specific
pathway reduces the number of multiple tests performed in the
analysis of a study population, thereby reducing the probability of
false positive associations and increasing the effective power of the
study. This kind of study design is particularly effective when
inflammation plays an important role in disease etiology and the
goal of the studies is to delineate genetic variations in inflammation
pathway to disease risk and/or progression. A related second
advantage of restricted pathway analysis is in study design. A large
proportion of investigators may not have access to the very large
number of subjects and multiple confirmation populations needed
to overcome false positive associations due to multiple testing in
genome-wide association studies. Studies restricted to a pathway
analysis permit the use of study populations that are not large
enough for use in whole-genome association studies. When target
diseases are not prevalent and inflammation is obviously involved
in disease etiology, researchers will gain the most out of an
inflammation pathway-specific study design. Although some genes
not related to inflammation found in whole-genome panels may
impart some risk to inflammation-associated diseases, associated
genetic variants would be anticipated to be concentrated in a panel
of SNPs in inflammation-associated genes. Therefore, the drawback
of potentially missing associated non-inflammation genes is offset by
the increased probability of detecting true associations in an
inflammation-restricted panel. Thirdly, pathway analysis is far less
expensive to perform than whole-genome analysis, especially
considering the cost for second, and/or third stage confirmation
studies needed to follow-up the significant results from an initial
screening in order to rule out false positive associations. Lastly, the
functional subpathways are also pre-defined with available biological
information.Thisrefined information providesinvestigators with the
opportunity to test gene-gene interactions within subpathways in
which synergistic interactions are more likely to be concentrated.
Additionally, the interplays between subpathways are also clearly
definedtoenableinvestigatorstotestbiologicallyfeasibleinteractions
between subpathways.
However, the results from this manuscript also have potential
utility for investigators who have more interests in surveying the
whole genome. For whole-genome analyses where there is a prior
hypothesis for inflammation being associated with the outcome,
the inflammation pathway and subpathways defined in this
manuscript may provide a framework for testing whether SNPs
in the inflammation pathway or subpathways as a whole are
overrepresented for significant associations to the outcome.
Although pathway networks can be constructed for whole-genome
analyses, such networks should be designed a priori before
beginning the study.
The WFINFLAM and WFINFLAM-YRI SNP array panels for
inflammation-associated genes provide a powerful tool for
analyzing the contribution of genetic variation in diseases that
have inflammatory components. Although whole-genome SNP
panels are currently available that include almost all of the genes
included in the WFINFLAM panels, the coverage of SNPs in
genes included in the WFINFLAM array is superior to the
coverage of currently available in whole-genome arrays, especially
for populations with African ancestry background. For researchers
who would like to use other genotyping platforms, the in-
flammatory gene list provided here would be a good starting
point for designing genotyping assays for other platforms.
Additionally, alternate approaches, other than r
2 based method,
for choosing SNPs based on the inflammatory gene list provided
here could also be considered. For example, researchers may
specifically focus on ‘‘high-prior’’ polymorphisms that are known
to be functional or have been previously linked to the specific
diseases under study, alone or in combination with the tSNPs
provided in the WFINFLAM panel. This approach may be more
efficient and powerful than the r
2 based method alone, especially if
the targeted ‘‘high-prior’’ polymorphisms are causal and their
linkage to the nearby tSNPs is incomplete.
In addition, precaution may be warranted for tSNP panels
designed based on the HapMap project. The transferability of the
LD patterns between populations studied in HapMap project and
other study populations may need to be validated. The trans-
ferability of HapMap-based selection of tSNPs using the reference
CEU population to several other diverse populations of European
ancestry has been demonstrated to be almost as effective for
overall SNP coverage in selected genomic regions or randomly
selected SNPs in the respective populations [46–50]. However, the
coverage with tSNPs based on HapMap CEU data for a small
subset of specific genes or SNPs may be lower in certain
populations despite overall similar coverage [51], particularly for
isolated indigenous populations [52]. Other than the data
provided by the HapMap project, we are not aware of complete
sequence variant information available for validation of the
transferability of tSNP panels that were designed based on
HapMap data to other study populations.
In summary, pathway analysis of inflammation-associated genes
is a powerful approach for determining genetic risk factors for both
inflammatory diseases and other diseases that may have an under-
appreciated modest inflammatory component, such as cancers.
The inflammation pathway gene list and functionally-defined
subpathways provide useful tools for assessing the impact of
genetic variations in inflammation pathways on disease risk, in
situations where either pathway-focused studies or genome-wide
analyses are employed.
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Selection of genes
Networks of genes involved in the regulation of the phases of
immune responses (described in Results and Table 2 ) were built
using Ingenuity Pathways Analysis (Ingenuity Systems: www.
analysis.ingenuity.com). Both pre-defined ‘canonical pathways’
and custom-built pathways based on our own queries for genes/
pathways not included in the canonical pathways were used to
establish these networks. Canonical pathways included: actin
cytoskeleton signaling; antigen presentation pathway; apoptosis
signaling; B cell receptor signaling; calcium signaling; cAMP
signaling; chemokine signaling; complement and coagulation
cascade; death receptor signaling; ERK/MAPK signaling; FcEp-
silon receptor signaling; G-coupled protein receptor signaling;
GM-CSF signaling; IGF-1 signaling; IL-10 signaling; IL-2
signaling; IL-4 signaling; IL-6 signaling; integrin signaling;
interferon signaling; JAK/STAT signaling; leukocyte extravasa-
tion signaling; natural killer cell signaling; NF-kB signaling; nitric
oxide signaling; notch signaling; p38 MAPK signaling; PI3K/Akt
signaling; PPAR signaling; protein ubiquination pathway; PTEN
signaling; SPK/JNK signaling; T cell receptor signaling; TGF-
b signaling; Toll-like receptor signaling.
These networks were then arranged into inflammation subpath-
ways by:
1) combining several networks together (e.g., ERK/MAPK, p38
MAPK, and SAPK/JNK canonical pathways into the
‘MAPK signaling’ inflammation subpathway; IL-2-, IL-4-,
IL-6-, IL-10-, Interferon-, GM-CSF-, IGF-1-, JAK/STAT6-,
and TGF-b- signaling canonical pathways into ‘cytokine
signaling’ inflammation subpathway; actin cytoskeleton-,
chemokine-, integrin-, and leukocyte extravasation- signaling
canonincal pathways into the ‘adhesion-extravasation-migra-
tion’ inflammation subpathway; etc.);
2) adding additional genes to bridge networks within a subpath-
way and to include appropriate genes not included in the
canonical pathways (e.g., additional cytokines and their
receptors were added to the ‘cytokine signaling’ inflammation
subpathway; additional integrins and chemokines/chemoat-
tractant molecules were added to the ‘adhesion-extravasa-
tion-migration’ inflammation subpathway; CD antigens
expressed by leukocytes not already included were considered
for addition to several subpathways; other missing genes/
pathways considered important by the panel of investigators,
such as the scavenger receptor network for ‘leukocyte
signaling’ inflammation subpathway and Nod1/CARD
family networks for ‘innate pathogen detection’ inflammation
subpathway; etc.);
3) trimming the networks of genes with low priority for inclusion
in the inflammation panel. Genes with lower priority include:
genes not expressed in immune cells or not directly involved
in cells responding to inflammation, including non-immune
cells (e.g., skeletal muscle-specific myosins in the actin
cytoskeleton signaling canonical pathway; calsequestrins
expressed mainly in various muscle cells, in the calcium
signaling canonical pathway; GH1 and GHR, growth
hormone expressed in pituitary gland and its receptor, and
NGFB and NGFR, nerve growth factor and its receptor, in
the NF-kB canonical pathway; etc.; MAPK8IP1, specific for
pancreatic cell function, in the PI3K/AKT canonical
pathway; etc.); genes with unknown function, though genes
with high homology to known inflammatory mediators were
considered (e.g., bcl-2 family homologs, IL-1b family
homologs). Special emphasis was placed on genes at nodes
for signaling to and from multiple pathways, most notably
genes in NF-kB, MAPK, and PI3K signaling pathways.
Choosing tagging SNPs
Tagging SNPs (tSNPs) for candidate genes were chosen using
Tagger server (http://www.broad.mit.edu/mpg/tagger/server.
html). The target sequences included genomic regions containing
the entire candidate genes, 5kb before transcription start site, and
2kb after the transcription end site, based on annotation in NCBI
Build 35. When candidate regions for two or more genes
overlapped, the combined genomic regions were used for choosing
tSNPs. Two separate lists of non-synonymous coding SNPs for the
CEPH population (CEU) and for the Yuruba population (YRI)
were downloaded from HapMap (rel21a_NCBI_Build35) and
forced in as tagging SNPs for ancestry-specific panels. Pair-wise r
2
threshold of 0.8 and MAF$5% were used. For genes without
genotype information from HapMap, SNPs in Affymetrix 500k
array, as well as SNPs with frequency data from the Innate
Immunity PGA (IIPGA) (http://innateimmunity.net/), were
manually chosen to be included in the list based on allele
frequencies and inter-SNP distance (the chromosomal positions
are based on IIPGA annotation because some of these genes/
SNPs were ambiguously mapped in build 35). Some tSNPs were
dropped out from the final list because they did not pass the
Affymetrix design review due to the following reasons: non-
biallelic SNPs, existing SNPs or ambiguous bases too close to the
SNP of interest, SNPs exceeding Tm ranges, or SNPs failing
BLAST searches. In the attempt to fill in the gaps due to tSNPs
failing design criteria, tSNPs for genes with dropped-out tSNPs
were chosen again by forcing out the tSNPs failing design review
and forcing in the remaining tSNPs when running Tagger. In
total, there are 12,011 SNPs in WFINFLAM panel for Caucasians
and 21,542 SNPs in WFINFLAM-YRI for African descents in
1027 inflammation-associated candidate genes that passed the
Affymetrix design review.
Estimation of genomic coverage by tagging SNPs
We used LdCompare (Hao 2006; http://www.affymetrix.com/
support/developer/tools/devnettools.affx) to estimate the cover-
age of the 1027 inflammation-associated candidate genes with
both WFINFLAM panel for Caucasians and WFINFLAM-YRI
panel for African descents. We have also computed the coverage of
several commercial genotyping arrays, including Affymetrix
Mapping 500K, Illumina HumanHap 550 and HumanHap 650,
for these 1027 genes. Single-marker coverage (pairwise r
2) and
multiple-marker coverage (multiple-marker r
2) were computed and
combined to estimate the coverage for the genomic regions
containing the entire candidate genes, 5kb before transcription
start site, and 2kb after the transcription end site. The summary
for the coverage for these genes in all these genotyping panels are
detailed in Table S6.
SUPPORTING INFORMATION
Table S1 List of genes included in WFINFLAM and their
associated sub-pathways
Found at: doi:10.1371/journal.pone.0001035.s001 (0.19 MB
XLS)
Table S2 Genes with big intronic regions
Found at: doi:10.1371/journal.pone.0001035.s002 (0.06 MB
XLS)
Inflammation Pathway Analysis
PLoS ONE | www.plosone.org 8 October 2007 | Issue 10 | e1035Table S3 SNPs chosen for the six genes without HapMap
genotyping data
Found at: doi:10.1371/journal.pone.0001035.s003 (0.04 MB
XLS)
Table S4 Annotation for tSNPs in WFINFLAM_CEU panel
Found at: doi:10.1371/journal.pone.0001035.s004 (1.64 MB
XLS)
Table S5 Annotation for tSNPs in WFINFLAM_YRI panel
Found at: doi:10.1371/journal.pone.0001035.s005 (3.39 MB
XLS)
Table S6 Summary for gene coverage of Wfinflam panels and
other genome wide association panels
Found at: doi:10.1371/journal.pone.0001035.s006 (0.04 MB
XLS)
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